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Abstract
Background: Pontocerebellar hypoplasia (PCH) is a heterogeneous group of diseases characterized by lack of
development and/or early neurodegeneration of cerebellum and brainstem. According to clinical features, seven
subtypes of PCH have been described, PCH type 2 related to TSEN54 mutations being the most frequent. PCH is
most often autosomal recessive though de novo anomalies in the X-linked gene CASK have recently been identified
in patients, mostly females, presenting with intellectual disability, microcephaly and PCH (MICPCH).
Methods: Fourteen patients (12 females and two males; aged 16 months-14 years) presenting with PCH at
neuroimaging and with clinical characteristics unsuggestive of PCH1 or PCH2 were included. The CASK gene
screening was performed using Array-CGH and sequencing. Clinical and neuroradiological features were collected.
Results: We observed a high frequency of patients with a CASK mutation (13/14). Ten patients (8 girls and 2 boys)
had intragenic mutations and three female patients had a Xp11.4 submicroscopic deletion including the CASK
gene. All were de novo mutations. Phenotype was variable in severity but highly similar among the 11 girls and
was characterized by psychomotor retardation, severe intellectual disability, progressive microcephaly, dystonia,
mild dysmorphism, and scoliosis. Other signs were frequently associated, such as growth retardation,
ophthalmologic anomalies (glaucoma, megalocornea and optic atrophy), deafness and epilepsy. As expected in an
X-linked disease manifesting mainly in females, the boy hemizygous for a splice mutation had a very severe
phenotype with nearly no development and refractory epilepsy. We described a mild phenotype in a boy with a
mosaic truncating mutation. We found some degree of correlation between severity of the vermis hypoplasia and
clinical phenotype.
Conclusion: This study describes a new series of PCH female patients with CASK inactivating mutations and
confirms that these patients have a recognizable although variable phenotype consisting of a specific form of
pontocerebellar hypoplasia. In addition, we report the second male patient to present with a severe MICPCH
phenotype and a de novo CASK mutation and describe for the first time a mildly affected male patient harboring a
mosaic mutation. In our reference centre, CASK related PCH is the second most frequent cause of PCH. The
identification of a de novo mutation in these patients enables accurate and reassuring genetic counselling.
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Pontocerebellar hypoplasia (PCH) is a heterogeneous
group of diseases characterized by lack of development
and/or early neurodegeneration of cerebellum and
brainstem. Indeed, PCH has been associated with chro-
mosomal abnormalities or metabolic disorders as well as
congenital muscular dystrophies [1-5]. According to
clinical features, seven subtypes of PCH have been
described (Table 1) [6-21].
Recently, the identification of several novel responsible
genes has added new insight to the characterization of
this group of disorders: three out of four subunits of the
tRNA splicing endonuclease complex, TSEN54, TSEN34
and TSEN2 have been shown to be involved in PCH2,
PCH4, PCH5 and in one patient with PCH1 [10,12,17].
PCH6 as well as some PCH1 are related to mutations in
the mitochondrial arginyl-tRNA synthetase RARS2 gene
[18-20]. The VRK1 gene was identified as responsible
for PCH1 but the reported patients seemed to be
affected by a very mild condition compared to the clini-
cal description of classical PCH1 [10]. In addition, simi-
lar neuroimaging aspects of the cerebellum and
brainstem have been observed in patients with large
deletions/mutations of the VLDLR gene and in Reelin-
associated lissencephaly with PCH [22-25].
More recently de novo anomalies in the X-linked gene
CASK (calcium/calmodulin-dependent serine protein
kinase) have been identified in patients with PCH,
mostly females, displaying intellectual disability and
microcephaly (MICPCH syndrome) [26-29].
In this study, we performed a systematic screening for
CASK mutations and deletions in 14 patients presenting
with PCH at neuroimaging but for whom the clinical
features differed from PCH1 or PCH2 (PCH4 and
PCH5). We observed a high frequency of CASK
abnormalities (13/14). We describe the clinical aspects
of these patients, including the second reported male
patient with an extremely severe PCH and clinical phe-
notype and the first mosaic mutation found in a mildly
affected male. Finally, we discuss the variability of the
clinical and radiological phenotypes and highlight the
characteristics of this recognizable syndrome.
Methods
Patients
We studied fourteen patients (12 females and two
males) referred to our reference centre for cerebellar
malformations. One girl was included in this series fol-
lowing the Array-CGH identification of a Xp11.4 submi-
croscopic deletion including CASK i nt h ec o u r s eo f
investigations for her intellectual disability. All other
patients (13) were investigated for the genetic diagnosis
of their PCH. Each patient had been examined by at
least one of us. Neither anterior horn cell disease nor
choreic movements were observed, ruling out PCH type
1 or 2. Before this study, the entire coding region of the
gene TSEN54, responsible for PCH2, had been systema-
tically sequenced in five of the patients and was normal.
MRI scans were systematically reviewed in all patients.
We have previously reported briefly two of the female
patients (Patients 4 and 10) [27]. For each patient and
their parents, blood samples were collected after obtain-
ing written informed consent. The investigations fulfilled
our institutions’ ethical rules for human studies.
Molecular analysis
Mutation analysis was systematically performed in all
patients, except in patient 1 in whom the Xp11.4 dele-
tion was previously found. The 27 CASK coding exons
and flanking intronic regions were PCR-amplified and
sequenced using 27 primer pairs (sequences available on
request). When a mutation was identified in a patient,
Table 1 Classification of PCH
PCH Type 1 Type 2 Type 3 Type 4 Type 5 Type 6 Type 7
Distinctive
features
Anterior horn cell
degeneration
Dyskinetic
movements
Seizures
(frequent)
Seizures
Short
stature
Optic
atrophy
Severe prenatal form
of PCH2 with:
Polyhydramnios
Contractures
Myoclonus
Apneic episodes
Early postnatal death
Severe prenatal form
of type 2 with:
Fetal onset of seizure-
like activity
Early postnatal death
Severe neonatal
encephalopathy with:
Hypotonia,
and inconstantly
Intractable seizures
Edema
Increased lactate
Mitochondrial
respiratory chain defects
Hypotonia
Apneic
episodes
Seizures
Vanishing
testis
Inheritance AR AR AR AR AR AR Unknown
Genes or
loci
VRK1 TSEN54 7q11-21 TSEN54 TSEN54 RARS2 unknown
TSEN54 TSEN34
RARS2 TSEN2
References [6-11] [6,7,11,12] [11,13,14] [7,11,12,15] [11,16,17] [11,18-20] [11,21]
In addition to the distinctive features reported in the table, microcephaly and intellectual disability are present in all types of PCH. AR: autosomal recessive
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Page 2 of 13parental DNAs were analyzed. Parental identities were
checked using 16 highly polymorphic markers (Power-
Plex 16 System, Promega). X-inactivation was deter-
mined by methylation analysis of the androgen receptor
polymorphic CAG repeat and the FMR1 gene CGG
repeats.
Whole blood sample (2.5 ml) from patient 8 was col-
lected into a PAXgene Blood RNA tube (PreAnalytiX;
Qiagen). Total RNA was isolated using the PAXgene
Blood RNA Kit (Qiagen) following manufacturer’s
guidelines and subjected to reverse transcription with
the SuperScript II Reverse Transcriptase kit (Invitrogen).
Specific primers for PCR amplification of CASK mRNA
were designed in exon 23 and exon 25, respectively,
based on their sequence data from the GenBank data-
base (GenBank accession number NM_003688.3). Analy-
s i so fP C Rp r o d u c t sw a sp e r f o r m e db yp u r i f y i n gs i n g l e
bands from agarose gel using a gel extraction kit (Qia-
Quick gel extraction kit; Qiagen), and sequenced
directly.
Array-CGH analysis
Four patients were found to be negative after mutation
screening and, therefore, were analyzed by Array-CGH
(Additional file 1).
Results
Overall, a CASK anomaly was identified in 13/14
patients (10 intragenic mutations and three Xp11.4 sub-
microscopic deletions).
CASK molecular analysis
Ten CASK mutations, including eight novel mutations,
were identified in 10 patients (eight females and two
males). Several types of mutations were observed: five
nonsense, one frameshift and four splice-site mutations
(Table 2). In all cases, parental DNA analysis confirmed
paternity and the de novo occurrence of the mutation.
Three of the four intronic mutations (patients 5, 9 and
13) were localized at the consensus donor or acceptor
canonical splice site and prediction software programs
predicted that the respective donor or acceptor site was
broken (Additional file 2). mRNA from these patients
was not available to perform CASK transcript analysis.
The splice mutation in patient 8 involved the fifth
nucleotide of intron 24 and we used four different
splice-site prediction software programs to predict the
effect of this mutation. The results obtained from these
in silico tools were consistent since they all predicted
that the wild type donor site was broken (Additional file
2). RT-PCR performed on mRNA from lymphocytes of
this patient revealed an aberrant transcript with skipping
of exon 24 (Figure 1). This aberrant transcript is in-
frame and is predicted to produce a protein which lacks
28 amino acids with the insertion of a Asp residue. The
exact pathogenic mechanism of this mutation is
unknown. In patient 12 a heterozygous profile was
observed suggesting a mosaic nonsense mutation in this
male patient. This profile was confirmed by analysis of a
second tissue (cheek swab) (Figure 2). Finally, apart
from the splice mutation in patient 8, all mutations
were classified as truncating mutations. CASK sequen-
cing in patients 2, 3 and 14 DNA was normal.
Array results
Array-CGH was performed in four patients. Since the
phenotype of patients 2 and 3 was strikingly similar to
that of patients with CASK mutations, we performed
Array-CGH in order to detect a submicroscopic deletion
involving CASK. In patient 1 Array-CGH was performed
as part of the diagnostic workshop of her intellectual
disability with pontocerebellar hypoplasia. An Xp11.4
deletion involving part of or the entire CASK gene was
detected in these three girls. The largest, a 2.9 Mb
Xp11.4-p11.3 deletion, included CASK as well as eight
RefSeq adjacent genes: USP9X, DDX3X, NYX, GPR34,
GPR82, MAOA, MAOB,a n dNDP (patient 2). The 575
kb deletion in patient 3 included the exon 1 of CASK
only but no others RefSeq genes. The smallest deletion
(patient 1) was 359 kb in size and removed the eight
first exons of CASK as well as the RefSeq genes GPR34
and GPR82. FISH analysis confirmed the deletions in
patients 1 and 3 whilst revealing a normal result for
their parents. Finally Array-CGH was performed in
patient 14 in spite of a different, more severe, phenotype
and was normal. Array-CGH results are summarized in
Additional file 1.
X-inactivation study
X-inactivation study was performed on 9/11 female
patients with CASK anomalies and showed random X-
inactivation.
Clinical phenotype of the 13 patients with CASK
anomalies
Clinical features are summarized in Table 2.
Phenotype of the 11 female patients
Birth occipitofrontal head circumference (OFC) was in
the normal or low normal range in all patients. Feeding
difficulties were frequently (8/11) noticed during the
first months of life (gastroesophageal reflux, sucking and
swallowing difficulties). In four patients these difficulties
and excessive drooling persisted at last examination (3-
14 years) and one patient had been fed via a gastro-
stomy tube since the age of five years. Progressive
microcephaly was present in all patients. Psychomotor
development was variable but intellectual development
Burglen et al. Orphanet Journal of Rare Diseases 2012, 7:18
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Page 3 of 13Table 2 Clinical and molecular data of our 13 patients with CASK mutation
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13
Sex/age at last
examination (years)
F/7 F/3 F/14 F/13 F/3 F/1 F/1 F/10 F/14 F/8 F/3.5 M/15 M/1.3
Birth (weeks) 39 40 40 40 40 39 41 40 41.5 40 39 41 40
Pregnancy pre-
eclampsia
N N IUGR INT N N N microcephaly
IUGR
NN N N
OFC/weight/length
at birth (SD)
-2/-1/-1 -3/-1/-1 -1/-1/-1 -1/-1/-1 -2/-1/-1.5 -1.5/-1/-1 -2/0/-0.5 -1/0/-0.5 -3/-2/-3 -1/-1/-1.5 0/0/0 -3/-1.5/-2 -2/0/-0.5
feeding difficulties ++ + + + NA + - - + + + + ++
Severe
developmental
delay/intellectual
disability
++++ + + + + + + + + +
Language bable bable bable bable NA TY TY 2 words 5-6 words 10 words - 12 words -
Ability to hold his
head
++++ + + + + + + N A + -
Ability to sit
(age in months)
13 - 36 20 18 - - 24 18 18 27 18 -
Ability to stand
(age in years)
3 - 5 (briefly) 4 (briefly) NA TY TY - - 2 NA 1.5 -
Method of
movement
walks on 4
legs
wheelchair
rolling wheelchair wheelchair walks with
support
wheelchair
TY TY wheelchair wheelchair walks, runs wheelchair walks bedridden
Hand control + - + + + + NA + + + NA + -
Spasticity ++ + + ++ + NA + ++ ++ - NA - +++
Dystonia - + + + + NA + + + - NA + +++
Choreoathethosis - - - - - - - - - - NA - -
Epilepsy - - - + - - + + - - - - +++
Stereotypies - NA + + NA NA - - + + + + -
OFC/height (SD) -6/-3 -6/-3.5 -6/-2 -7,5/-4 -5/NA -3/1 -4/-1 -6.5/-4.5 -6/-4 -4/-3 -5/0 -3.5/-3.5 -6/-2
ophthalmologic
anomalies
strabismus ret OA meg, OA
SP ret
low vision
ret meg
bil glau
- myopia SP ret low
vision
- strabismus - OA
Abnormal ERG - + NA + + NA NA - ++ + NA NA -
Hearing N unil SN
deaf
NA N unil SN deaf NA N bil SN
deaf
NN N N -
Sleep disturbance ++ ++ ++ + NA NA ++ - ++ ++ ++ - -
Scoliosis + + + + NA NA - - + - - - -
Extremities N N N long
fingers
and toes
N long
fingers
N N clinodactyly,
overlapping
toes
hypoplastic
nails
slender
hands and
feet
2-3 syndactyly long slender
fingers with
retractions
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3Table 2 Clinical and molecular data of our 13 patients with CASK mutation (Continued)
Dysmorphism NA + + + NA + + + + + NA + +
Mutation Xp11.4
deletion
0.3 Mb
Xp11.3-
p11.4
deletion
3M b
Xp11.4
deletion
0.5 Mb
c.1968 G
> A (p.
Trp656*)
c.2040-2A >
G
c.2080 C
> T (p.
Gln694*)
c.2074 C
>T
(p.
Gln692*)
c.2302 + 5
G>A
c.2039 + 1 G
>T
c.1970 G >
A (p.
Trp657*)
c.1501dupA
(p.Met501fs)
c.[ =/316 C >
T] (p.Arg106*)
mosaic
c.278 + 1 G >
A
Exon/intron exons 1-8 exons 1-
27
exon 1 exon 21 intron 21 exon 22 exon 22 intron 24 intron 21 exon 21 exon 15 exon 4 intron 3
X-inactivation NA random random random random random random random random random NA na na
Parents de novo NA de novo de novo de novo de novo de novo de novo de novo de novo de novo de novo de novo
The mutation nomenclature follows the mutation nomenclature rules of the Human Genome Variation Society http://www.hgvs.org version 2.0 and is based on RefSeq NM_003688.3 with +1 as the A of the ATG
initiation codon
F: female; M: male; N: Normal; IUGR: intrauterine growth retardation; INT: increased nuchal translucency; +: present. ++: present, moderate; +++: present, severe; -: absent; NA: non available; TY: too young; ret:
retinopathy; OA: optic atrophy; meg: megalocornea; SP ret: salt-and-pepper retinopathy; glau: glaucoma; bil: bilateral; unil: unilateral; SN deaf: sensorineural deafness; na: non applicable
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3was severely impaired in all patients. All patients had
eye contact and acquired head control in the age range
of three to 24 months. Purposeful hand control was
achieved in six patients. Among the nine patients older
than three years, eight were able to sit (acquired at one
to three years), only one was able to walk unaided and
seven patients were wheelchair bound. Language was
nearly absent in 7/9 of the older patients and reduced to
a few words in two. Neurologic examination displayed
extrapyramidal symptoms (dystonia, buccolingual dyski-
nesia) and/or spasticity in 8/11. One patient had axial
hypotonia and peripheral hypertonia in the first years
but presented with near normal neurological examina-
tion at 11 years. The behavioral phenotype included
sleep disturbances (multiple awakening during the first
years) in at least seven patients and hand stereotypies
and self-biting in five. Epilepsy was present in three
patients: two had atypical absences and patient 7 had
West syndrome in infancy. One patient presented with
disabling massive myoclonias. Scoliosis and constipation
were frequent. Various ophthalmologic anomalies were
noted: retinopathy (5, all had abnormal ERG and two
had salt-and-pepper retinopathy), optic atrophy (2),
glaucoma/megalocornea (2) and nystagmus (1). Three
patients had sensorineural hearing loss. One patient
developed type 1 diabetes mellitus at the age of 14
years. Minor dysmorphism was observed: round face
tending to lengthen in older patients, well-drawn arched
eyebrows, large nasal bridge, protruding maxilla and
maxillar incisors in older patients (Figure 3). No other
visceral malformation was detected in any patient.
Phenotype of the two male patients
Patient 13 presented with severe neonatal hypotonia,
along with intractable seizures, distal contractures, long
fingers and diaphragmatic eventration. OFC was initially
normal, followed by postnatal microcephaly, reaching
-6SD at the age of 16 months. Minor dysmorphic fea-
tures were noted: retrognathism, high arched palate,
downslanting palpebral fissures, broad nasal bridge, low-
set ears with prominent lobules, hypoplastic scrotum,
edema of the hands and feet. He had no visual contact
and communication skills were limited to smiling.
Examination showed profound hypotonia with no head
control, spastic tetraparesia and severe dystonia with
opisthotonos. Seizures were refractory to treatment and
consisted of daily spasms and tonic seizures with sup-
pression-burst. He had severe gastroesophageal reflux
and swallowing difficulties requiring gastrostomy.
Ophthalmologic examination showed very hypoplastic
and pale optic discs. Visual evoked responses were
absent. Brainstem auditory evoked potential showed
normal wave I but nearly absent central responses.
Patient 12 was born at term after a normal pregnancy
with normal parameters. His psychomotor development
was delayed and walking was achieved at four years. At
age 15, he had severe intellectual disability, his language
was limited to a few words but he used non verbal com-
munication tools. He was able to walk independently,
had dystonia, stereotypic movements and buccofacial
b
P8 C
300
200
100
400
bp
N
a
M
C
Exon 25 Exon 23
Exon 23 Exon 24
P8
Figure 1 RT-PCR analysis in patient 8 (mutation c.2302 + 5 G >
A), showing exon skipping and aberrant transcript. a. RT-PCR
products were amplified from cDNA of patient 8 and from one
healthy individual using primers in exon 23 and in exon 25. The
arrow indicates an aberrant sized product in patient 8 in addition to
normal sized transcript observed in patient 8 and in healthy control.
M marker, P8 patient 8, C control, N negative control. b. The PCR
products were purified and sequenced. Sequence chromatograms
from normal sized amplicon with normal sequence exon 23-24-25,
and from abnormal amplicon, showing absence of exon 24.
EXON 4
P12 (cheek swab)
Mother
P12 (lymphocytes)
Father
Figure 2 Sequence analysis of exon 4 amplified from DNA
obtained from lymphocytes and cheek swab of patient 12 and
from lymphocytes of his parents. The upper two sequence
profiles (patient) show low signals for the mutant variant
superimposed on the wild-type sequence (arrow). The lower two
sequence profiles (parents) show the wild type sequence.
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Page 6 of 13dyskinesia. His OFC and height reached -3.5 SD.
Ophthalmological examination and auditory testing
were normal.
MRI features
In all patients, MRI showed hypoplasia of the brainstem
and cerebellum (Figure 4). The brainstem hypoplasia
was associated with sparing of the superior part of the
pons and mainly concerned the inferior part. The cere-
bellar hypoplasia involved similarly the vermis and
hemispheres which were often asymmetric. The severity
of cerebellar hypoplasia was extremely variable, allowing
the definition of a severity gradient. Patient 13 had the
most severe cerebellar involvement with near absent
cerebellar hemispheres. His brainstem was very thin but
with preservation of slight anterior relief at the upper
part of the pons. At the opposite end of the spectrum,
patients 9 to 12 had mild cerebellar hypoplasia. In three
patients anomalies were stable on two successive MRIs.
Gyration and basal ganglia nuclei were normal.
Discussion
Calcium/calmodulin-dependent serine protein kinase
(CASK) is a member of the membrane-associated gua-
nylate kinase (MAGUK) family involved in synapse for-
mation and in the regulation of gene expression,
including Reelin which is critical in brain development
[30].
Using Array-CGH, two groups identified Xp11.4 sub-
microscopic deletions involving the CASK gene in girls
affected with intellectual disability and microcephaly
[31,32]. Najm et al. reported three novel female patients
with CASK deletions or disruption and described more
precisely the phenotype including cerebellar and brain-
stem hypoplasia [26]. Furthermore in two patients with-
out Xp11.4 deletions they identified de novo CASK
A BC
DE F
Figure 3 Facial features of CASK-positive patients. A and B: patient 8 (1 year (A) and 4 years (B)). C: patient 7 (18 months). D: patient 12 (13
years). E: patient 9 (13 years). F: patient 4 (12 years). Note minor facial dysmorphism: round face, small chin, well-drawn eyebrows in the younger
patients; longer face, high and large nasal bridge, long nose, protuding maxilla, in the older patients. Signed informed consent was obtained
from the parents of the affected children for publication of the images.
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Figure 4 MRIs in patients. A. Sagittal images showing spectrum of vermis and pons hypoplasia. Number represents the number of the patient.
Figure 9 shows MRI of patient 9 at age 4 months and figure 9b patient 9 at age 11 years. Note that in all patients, the pons is very small but
has a relative sparing of his buldging, mainly in its superior part. Hypoplasia predominates at the inferior part of the pons. Vermis hypoplasia is
very variable, severe in patient 13, very slight in patient 10-11-12 and predominates at the inferior part. V4 is open in most cases. B. Coronal
images showing spectrum of cerebellar hemispheric hypoplasia. Number represents the number of the patient. Hemispheres are frequently
asymmetric. Note that the vermis does not protrude from the hemispheres indicating similar involvement of the vermis and the hemispheres.
This pattern is different from that of PCH2 in which the vermis is relatively spared leading to the classic image of “dragonfly”, the protruding
vermis being the body of the dragonfly and the hemispheres, the wings. There is no progression of the lesions between successive MRI in
patient 9.
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Page 8 of 13intragenic mutations. One of the patients was a boy who
was affected with a very severe form of PCH. Thirty-
three further female patients with PCH and CASK de
novo loss-of-function anomalies have been reported
[27-29]. In addition, CASK hypomorphic inherited
mutations have been described in patients, mainly male,
affected with intellectual disability and not featuring
MICPCH [33-35].
In this study, we describe 13 patients (11 girls and 2
boys) affected with PCH and harboring heterozygous or
hemizygous CASK anomalies. Among a large series of
PCH patients that were referred to us, we prioritized the
screening of the CASK gene in these patients since clini-
cal criteria for PHC1 and PCH2 were absent. We parti-
cularly noted the differences in the clinical features
between our patients and those of PCH2 patients.
Indeed, patients had no incessant choreic movements,
were hypotonic rather than hypertonic, had a less severe
psychomotor retardation and had features not usually
observed in PCH2 (sensorial involvement as well as
slight dysmorphism). Sequencing allowed us to identify
10 CASK intragenic mutations, in eight girls and two
boys. All mutations were private, with no identified hot-
spot. Nine were inactivating mutations and one was pre-
dicted to lead to a large in-frame deletion. In three
other female patients Array-CGH analysis revealed a
Xp11.4 submicroscopic deletion involving part of or the
entire CASK gene.
The patients with a CASK mutation showed a charac-
teristic phenotype with some variability concerning the
severity and the associated sensorial involvement. All
had neonatal feeding difficulties, intellectual and motor
disabilities and progressive microcephaly. Most had pro-
found disabilities but two patients are able to use a few
words and have acquired autonomous walking. Postnatal
microcephaly was severe in seven patients (OFC < -6SD)
but OFC ranged between -3 to -4 SD in four. Four
patients had epilepsy and this was refractory in one.
Ophthalmological abnormalities were present in at least
six patients and sensorineural hearing loss in two. The
association with a diabetes mellitus observed in one
patient has not been previously reported and could be
co-incidental. All our patients with a CASK mutation
presented slight but homogeneous dysmorphic features.
As reported by Moog et al., we observed a broad nasal
bridge in the majority of patients and a micrognathism
in the younger. A round face tending to lengthen in
older patients, well-drawn arched eyebrows and protrud-
ing maxilla and maxillar incisors in older patients repre-
sented the major facial findings in our series. These
findings were also frequently observed in patients pre-
sented by Najm et al and Moog et al [26,29].
In one patient we failed to detect any CASK mutation
or deletion. This patient had a very severe phenotype
characterized by severe encephalopathy, almost no psy-
chomotor acquisition, epilepsy, absence of choreoatheto-
sic movements and premature death. MRI revealed
severe pontocerebellar hypoplasia as well as severe sub-
tentorial atrophy. A previous pregnancy has been termi-
nated because of PCH suggesting the possibility of
recessive disease.
All our patients had severe intellectual and motor dis-
abilities with PCH but at varying degrees. A correlation
between the clinical severity and the MRI findings may
be discussed. This correlation is obvious for the two
male patients, notably due to the severity of patient 13.
He had the most severe clinical features including
refractory epilepsy, optic atrophy and almost no psycho-
motor acquisition at age of 16 months and his MRI
showed the most severe PCH. By contrast, the male
w i t ham o s a i cm u t a t i o n( p a t i e n t1 2 )w a sa b l et ow a l k
from the age of three years and use a few words. He
had no epilepsy or spasticity, his microcephaly was mod-
erate (-3.5 SD) and his MRI showed mild cerebellar
hypoplasia. This correlation is less clear however in
female patients. Nevertheless, the female patient with
the mildest clinical features, patient 10, had a clinical
phenotype very similar to that of the male patient 12
and also had mild cerebellar hypoplasia. Moreover, in
previously reported female patient series the acquisition
o fw a l k i n ga n dt h ea b i l i t yt ou s eaf e ww o r d ss e e m st o
correlate with a less severe cerebellar hypoplasia (Patient
6 in Hayashi at al.; patients 7, 15, 20, 21 and 24 in Moog
et al) [28,29]. However this clinicoradiologic correlation
cannot be relied upon entirely since patient 11, while
still young, had a mild cerebellar hypoplasia but she was
unable to walk. As reported by Takanashi et al., we
observed a reduced area of the cerebrum, pons and cer-
ebellum, but a sparing of the corpus callosum in most
patients [36].
Aside from this partial clinicoradiologic correlation,
we failed to identify any clear genotype-phenotype cor-
relation in this series, except for the non mosaic male
patient, who is hemizygous for the splice mutation and
has the most severe phenotype. The severity of the dis-
ease in patients with a CASK deletion was very similar
to patients with intragenic mutations regarding motor
and intellectual disability, epilepsy, MRI anomalies and
hearing and visual defects, even when the deletion
involved nine other genes. Furthermore, two very close
mutations (p.Trp657* and p.Trp656*) were observed in
two unrelated girls: one had the milder phenotype,
acquired independent walking at age 3, was able to run
and to use a few words at 8 years and the second was a
severely affected girl who had acquired no language and
was unable to walk.
Finally, all girls and boys with inactivating CASK
mutations presented with a recognizable phenotype
Burglen et al. Orphanet Journal of Rare Diseases 2012, 7:18
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Page 9 of 13Table 3 CASK intragenic mutations identified in our series and in literature (ref seq NM_003688.3)
Type of mutation Exon Mutation Protein change predicted Family Sex Phenotype Reference
Nonsense 2 c.79 C > T p.Arg27* nd F MICPCH [28]
4 c.316 C > T p.Arg106* de novo/de novo F/M MICPCH [28], This study
5 c.379 C > T p.Glu127* nd F MICPCH [29]
17 c.1639 C > T p.Gln547* nd F MICPCH [29]
21 c.1915 C > T p.Arg639* de novo F MICPCH [26]
21 c.1968 G > A p.Trp656* de novo F MICPCH [27], This study
21 c.1970 G > A p.Trp657* de novo F MICPCH [27], This study
22 c.2074 C > T p.Gln692* nd/de novo F MICPCH [29], This study
22 c.2080 C > T p.Gln694* de novo F MICPCH This study
27 c.2632 C > T p.Gln878* de novo F MICPCH [28]
Frameshift 2 c.68delT p.Phe23fs de novo F MICPCH [29]
3 c.243_244delTA p.Tyr81* nd F MICPCH [28]
15 c.1501dupA p.Met501fs de novo F MICPCH This study
16 c.1578delG p.Arg526fs de novo F MICPCH [27]
Splice defect I2 c.173-2A > C Skipping of exon 3 leading to
premature stop codon
de novo F MICPCH [29]
I3 c.278 + 1 G > A Exon skipping ?
a de novo M MICPCH This study
I4 c.357-1 G > A Skipping of exon 5 or skipping
of exon 5
and insertion of partial intron
5
de novo F MICPCH [28]
I5 c.430-2A > T Exon skipping ?
a nd F MICPCH [29]
I8 c.831 + 2 T > G Exon skipping ?
a de novo F MICPCH [29]
9 c.915 G > A Skipping of exon 9 leading to
an in-frame deletion
of 28 amino-acids
Mother normal M MICPCH [26]
I17 c.1668 + 1 G > A Exon skipping ?
a de novo F MICPCH [29]
I21 c.2039 + 1 G > T Exon skipping ?
a de novo F MICPCH This study
I21 c.2040-1 G > C Skipping of partial or entire
exon 22
de novo F MICPCH [28]
I21 c.2040-2A > G Exon skipping ?
a de novo F MICPCH This study
22 c.2129A > G p.710_718del
splicing defect leading to an
in-frame deletion of 9 amino
acids
familial M ID-nystagmus [33,35]
I24 c.2302 + 5 G > A Skipping of exon 24 leading to
an in-frame deletion of 28
amino acids and insertion of
a Asp residue
de novo F MICPCH This study
I25 c.2521-2A > T Splicing defect leading to 2 in-
frame deletions (3 amino
acids; 28 amino acids)
familial M ID-nystagmus [35]
Missense 2 c.83 G > T p.Arg28Leu Familial M/F FG syndrome [34]
8 c.802 T > C p.Tyr268His Familial M ID-nystagmus [33,35]
13 c.1186 C > T p.Pro396Ser Familial M/F ID [33,35]
23 c.2168A > G* p.Tyr723Cys
b Familial M/F ID-nystagmus [35]
27 c.2740 T > C** p.Trp914Arg
c Familial M ID [33,35]
In bold, mutations found in our patients (Mutations are named according to the guidelines of the Human Genome Variation Society (HGVS) Version 2.0)
aExperimental data non available.
bThis mutation was reported as Y728C by Hackett according to reference sequence ENST00000378163 but the nucleotide
substitution is c.2168A > G and the mutation Y723C according to the reference sequence NM_003688.3.
cThis mutation was reported as W919R by Hackett
according to reference sequence ENST00000378163 but the nucleotide substitution is c.2740 T > C and the mutation W914R according to the reference
sequence NM_003688.3. nd: not done. F: female; M male; MIC-PCH: mental retardation, microcephaly and pontocerebellar hypoplasia; I: intron; ID: intellectual
disability
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Page 10 of 13characterized by severe postnatal microcephaly, moder-
ate to severe motor and intellectual disability, feeding
and sleep difficulties, frequent ophthalmological anoma-
lies and PCH on MRI. The absence of anterior horn
involvement excluded PCH1. Severe post-natal microce-
phaly and dystonia as well as some neuroradiological
features (dragonfly-like cerebellum, hypoplasia of the
pons) could be suggestive of PCH2. However, PCH2
and CASK-related PCH are distinct entities. Indeed,
PCH2 patients have a more severe clinical course (near
absent development and choreic movements), and do
not present with ophthalmologic abnormalities (glau-
coma, megalocornea, optic atrophy, and retinopathy),
hearing loss or facial dysmorphism, which are frequently
found in CASK mutated patients. Furthermore, analysis
of the MRI gives additional clues showing relative spar-
ing of the pons, asymmetry of the cerebellar hemi-
spheres as well as vermian and cerebellar involvement.
In PCH2 there is a relative sparing of the vermis but
cerebellar hemispheres and brainstem are severely
affected with a flat pons [9,29,37]. If there is any doubt,
the major TSEN54 mutation (A307S) observed in a
majority of PCH2 patients, can easily be ruled out.
Only three male patients with MICPCH and de novo
CASK mutations have been reported [this report, 26]
suggesting a possible lethality in most affected male
patients. The two male patients with MICPCH and non
mosaic CASK mutations presented with a severe PCH,
severe neurological impairment with near absent devel-
opment, absence of sucking and swallowing, optic atro-
phy, refractory epilepsy and edema of the hands and
feet in one [26]. This phenotype is reminiscent of PEHO
syndrome but the presence of severe PCH unlike pro-
gressive cerebellar atrophy should prompt to look for
CASK mutations [38].
To date, two groups have reported molecular analysis
results in their cohort of PCH patients [9,27]. These stu-
dies showed that the majority (45 to 63%) of patients
were affected with PCH2/4 with mutations in one TSEN
gene, mostly the A307S mutation in TSEN54.I no u r
cohort of 40 PCH patients referred to our reference cen-
ter, CASK-related PCH was the second most frequent
cause (13/40, 32%) behind PCH2/4 (18/40, 45%, manu-
script under preparation).
Several groups have reported CASK mutations in male
patients with other phenotypes: FG syndrome and X-
linked mental retardation (XLMR) with or without nys-
tagmus [33-35]. The mutations reported in these
patients were missense or splicing mutations resulting
in in-frame deletions and were all familial. The affected
boys had mild to severe intellectual disability without
severe motor impairment and without microcephaly.
Nystagmus was a frequent feature and some patients
had seizures, strabismus, optic disc pallor, visual impair-
ment or dysmorphic features. In those families, most
females had no (10/13) or mild (2/13) intellectual dis-
ability and one was severely retarded. Data concerning
M R Ia r ea v a i l a b l ei no n l y2 / 2 5m a l ep a t i e n t s ,o n eo f
whom has been described as normal and the other
showing cerebellar hypoplasia and pachygyria [35]. The
male patient with cerebellar hypoplasia had severe intel-
lectual disabilities, nystagmus and a small OFC at the
3
rd centile, but no motor abnormalities or seizures were
reported and his mutation was inherited. More details
concerning the MRI features of male patients with
hypomorphic CASK mutations would be contributive to
determine which mentally retarded patients should be
tested for CASK mutations.
Therefore the spectrum of phenotypes associated with
CASK mutations is very large in males, from lethality or
severe neurologic impairment with PCH to isolated
intellectual disability. In females, depending on the type
of mutation, it extends from normal to severely mentally
retarded patients with motor disabilities related to PCH.
Conclusion
Genotype-phenotype correlations in our patients and
previously published patients confirm that CASK inacti-
vating mutations are de novo and are associated with
PCH and microcephaly in females and a severe pheno-
type in males while missense mutations or in-frame
deletions are observed in males and rarely in females
with variable degrees of XLMR with or without
nystagmus.
As patients with non-inactivating mutations have a
non specific intellectual disability, it seems difficult to
determine the clinical criteria which would allow the
selection of patients for sequencing, particularly in
sporadic cases. On the other hand, patients with inacti-
vating mutations have a recognizable phenotype consist-
ing of a specific form of PCH. Consequently CASK
analysis should be performed in girls presenting with
intellectual disability, microcephaly and PCH, in the
absence of symptoms suggesting PCH2 (severe encepha-
lopathy with choreoathetosis) and particularly in the
presence of ophthalmological anomalies such as optic
atrophy or glaucoma. Furthermore we consider that
CASK exonic deletion or duplication screening must be
part of the strategy when looking at CASK anomalies in
a patient with a suggestive phenotype. The identification
of a de novo mutation allows to give a reassuring genetic
counseling, whilst PCH is most often autosomal
recessive.
Abbreviation
PCH: Pontocerebellar hypoplasia.
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Additional file 1: Results of Array-CGH. All deletions were mapped
according to the March 2006 assembly of the UCSC genome browser
(NCBI Build 36.1/hg18; http://genome.ucsc.edu).
Additional file 2: Prediction of pathogenicity obtained for the four
intronic mutations using four splice-site prediction software
programs.
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